divislab glp-1 novo nordisk relation drug shows less lean mass loss than rivals, study says Novo Nordisk is slashing GLP-1

After the knockout of the GLP-1R gene, in transgenic mice expressing human GLP-1R in pancreatic islets and pancreatic ductal cells restored cAMP and serine threonine kinase (Akt) phosphorylation levels in isolated islets, increased GLP-1-stimulated insulin secretion and GLP-1R-dependent -cell proliferation, and promoted transgenic mice for glucose regulation in response to feeding (Lamont et al., 2012)

Baseline and ongoing laboratory monitoring should include: Glucose parameters : A1C and fasting glucose at baseline, 3 months, and every 3 months thereafter until stable, then potentially less frequently per ADA guidelines

However, further research is required to fully comprehend the mechanisms and therapeutic implications

The appropriate response is not avoidance, but disciplined translational design that aligns mechanism, indication, and risk tolerance

doi: 10.3389/fcell.2024.1452824 Received 21 June 2024 Accepted 03 September 2024 Published 11 September 2024 Volume 12 - 2024 Edited by Patrice X